Abstract

BackgroundCarbapenem-resistant Enterobacteriaceae pose a serious threat to public health worldwide, and the role of companion animals as a reservoir is still unclear.AimsThis 4-month prospective observational study evaluated carriage of carbapenem-resistant Enterobacteriaceae at admission and after hospitalisation in a large referral hospital for companion animals in Switzerland.MethodsRectal swabs of dogs and cats expected to be hospitalised for at least 48 h were taken from May to August 2018 and analysed for the presence of carbapenem-resistant Enterobacteriaceae using selective agar plates. Resistant isolates were further characterised analysing whole genome sequences for resistance gene and plasmid identification, and ad hoc core genome multilocus sequence typing.ResultsThis study revealed nosocomial acquisition of Escherichia coli harbouring the carbapenemase gene bla OXA-181, the pAmpC cephalosporinase gene bla CMY-42 as well as quinolone resistance associated with qnrS1 and mutations in the topoisomerases II (GyrA) and IV (ParC). The bla OXA-181 and qnrS1 genes were identified on a 51 kb IncX3 plasmid and bla CMY-42 on a 47 kb IncI1 plasmid. All isolates belonged to sequence type ST410 and were genetically highly related. This E. coli clone was detected in 17 of 100 dogs and four of 34 cats after hospitalisation (21.6%), only one of the tested animals having tested positive at admission (0.75%). Two positive animals were still carriers 4 months after hospital discharge, but were negative after 6 months.ConclusionsCompanion animals may acquire carbapenemase-producing E. coli during hospitalisation, posing the risk of further dissemination to the animal and human population and to the environment.

Highlights

  • Companion animals nowadays share the owner’s home environment and benefit from intensive veterinary care in case of serious illness

  • Even the last resort antibiotics of human medicine such as carbapenems may be used in companion animals in Switzerland to treat infections refractory to any other standard antimicrobial used in veterinary medicine (Ordinance on Veterinary Medicinal Products, SR 812.212.27, Art. 6)

  • Carriage of CP E. coli was detected in only one dog and none of the cats at admission (0.75%; 95% confidence interval (CI): 0–2.2)

Read more

Summary

Introduction

Companion animals nowadays share the owner’s home environment and benefit from intensive veterinary care in case of serious illness. Even the last resort antibiotics of human medicine such as carbapenems may be used in companion animals in Switzerland to treat infections refractory to any other standard antimicrobial used in veterinary medicine (Ordinance on Veterinary Medicinal Products, SR 812.212.27, Art. 6) Such treatments pose the risk of selecting resistance to these classes of antibiotics in Enterobacteriaceae through the acquisition of plasmid-mediated cephalosporinase genes (e.g. bla , CTX-M bla CMY) and fluoroquinolones resistance genes (e.g. qnr, aac-(6)-Ib-cr), and through chromosomal mutations in the promotor region of the AmpC β-lactamase and in the quinolone resistance-determining region (QRDR) of the topoisomerases II (GyrA) and IV (ParC) [1,2]. Conclusions: Companion animals may acquire carbapenemaseproducing E. coli during hospitalisation, posing the risk of further dissemination to the animal and human population and to the environment

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call